Adlyxin Starter Kit Update: What Patients Need to Know in 2026

If you've been trying to fill or refill the Adlyxin Starter Kit at your pharmacy, this page has the complete update you need. The short answer: Adlyxin (lixisenatide) is gone from the US market permanently. But understanding the full picture helps you make informed decisions about your diabetes care in 2026.

The Official Status: Permanent Discontinuation, Not a Shortage

On October 20, 2022, Sanofi — the manufacturer of Adlyxin — announced it would discontinue the sale of lixisenatide in the United States. The last date of availability was January 1, 2023. Unlike a drug shortage, where supply is temporarily disrupted due to manufacturing problems, this was a voluntary business decision by Sanofi to exit the US market with this product.

The FDA Drug Shortage database does not list Adlyxin because this is not classified as a shortage — it is a market withdrawal. No regulatory action can require Sanofi to resume manufacturing or distribution of a voluntarily discontinued product.

Why Did Sanofi Discontinue Adlyxin?

Sanofi cited two key factors: the availability of alternative treatments for type 2 diabetes, and the overall financial performance of Adlyxin. Since the drug launched in 2016, the GLP-1 market changed dramatically. Once-weekly agents like semaglutide (Ozempic, 2017) and dulaglutide (Trulicity, 2014) became standard of care and quickly overtook daily injectables in prescriber preference.

Lixisenatide's modest A1C reduction of approximately 0.79% could not compete with the 1.0 to 1.8% reductions achieved by semaglutide or the dual GIP/GLP-1 action of tirzepatide. With the explosion of GLP-1 prescribing driven by obesity management demand starting in 2023, lixisenatide's niche as a short-acting daily prandial GLP-1 became economically unsustainable for Sanofi to maintain in the US.

Timeline of the Adlyxin Discontinuation

July 2016: FDA approves Adlyxin (lixisenatide) as an adjunct to diet and exercise for type 2 diabetes in adults

November 2016: FDA approves Soliqua 100/33, a combination of lixisenatide and insulin glargine

2017–2022: Adlyxin faces increasing competition from once-weekly GLP-1 agents; market share declines

October 20, 2022: Sanofi announces discontinuation of Adlyxin in the United States

January 1, 2023: Adlyxin officially discontinued in the US; no new supply distributed

Late 2023: Lyxumia (same drug, European brand name) also discontinued in the UK

What This Means for Patients Currently Using Adlyxin

If you are still looking for Adlyxin at pharmacies in 2026, you will not be able to fill it. Any pharmacy that tells you it is out of stock is correct — and the medication is not expected to return. The most important immediate step is to contact your prescribing doctor to discuss transitioning to a suitable GLP-1 alternative. Do not abruptly stop taking GLP-1 therapy without medical guidance, as blood sugar levels may rise.

Does Lixisenatide Still Exist in Any Form?

Yes. Soliqua 100/33 (insulin glargine/lixisenatide) is still on the US market as of 2026. Soliqua combines lixisenatide with insulin glargine in a single daily injection and is indicated for adults who are inadequately controlled on basal insulin (less than 60 units per day) or on lixisenatide alone. Patients who need both basal insulin and GLP-1 coverage may find Soliqua to be an appropriate option.

Recommended Next Steps for Patients

Contact your doctor as soon as possible to discuss alternative GLP-1 medications

Ask your doctor if Soliqua 100/33 is appropriate for you if you also require basal insulin

Discuss options like Ozempic (semaglutide), Trulicity (dulaglutide), or Victoza (liraglutide)

Check your insurance formulary for coverage of alternative GLP-1 medications

Use medfinder to locate your new prescription at pharmacies near you once your doctor has sent it in

Finding Your New Medication

Once your doctor prescribes an alternative GLP-1 medication, finding it in stock can be its own challenge. GLP-1 agents like Ozempic have experienced intermittent availability issues at pharmacies. medfinder calls pharmacies near you to check which ones can fill your specific prescription. For a full comparison of what to take instead, see our guide to Adlyxin alternatives in 2026.